-

AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer

LYON, France--(BUSINESS WIRE)--Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology.

The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy.

Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show :

  • Favorable safety with no dose‑limiting toxicities (DLTs) observed.
  • Promising early efficacy, including 100% disease control rate (DCR) in RECIST.
  • Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses.

Exploratory analyses are ongoing to further characterize tumor–immune dynamics and identify predictive biomarkers supporting subsequent stages of clinical development.

Together, these results support continued advancement of STC‑1010 toward later‑stage evaluation and validate the SGC technology as a scalable, “off-the-shelf” approach for high unmet-need solid tumors.

Poster Details

  • Poster Title: “From preclinical models to first‑in‑human evaluation of STC‑1010 immunotherapy in unresectable advanced colorectal cancer”
  • Session: First‑in‑Human Phase I Clinical Trials
  • Date & Time: April 20, 2026 | 9:00 AM – 12:00 PM
  • Location: Poster Section 50
  • Poster Board Number: 11
  • Abstract Number: CT051

Authors : Diego TOSI 1, Antoine ITALIANO 2, Antoine HOLLEBECQUE 3, Benoît YOU 4, Iseulys RICHERT 5, Benoit PINTEUR 5, Paul BRAVETTI 5, François GHIRINGHELLI 6

1 Montpellier Cancer Institute, Montpellier, France; 2 Bergonié Institute, Bordeaux, France; 3 Gustave Roussy Institute, Villejuif, France; 4 Hospices Civils de Lyon, Pierre-Bénite, France; 5 Brenus Pharma, Lyon, France 6Georges-François Leclerc Cancer Center, Dijon, France

About Brenus Pharma

Brenus Pharma develops an off-the-shelf platform advancing novel modalities in immuno-oncology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response adapting to tumor evolution in hard-to-treat solid tumors – where current therapies fall short.

www.brenus-pharma.com

Contacts

contact@brenus-pharma.com

Industry:

Brenus Pharma

Release Versions
EnglishSpanishGermanFrenchItalian (Summary)Dutch (Summary)
Hashtags
#Biotech
#CancerResearch
#ClinicalTrials
#EuropeanBiotech
#FrenchTechHealth
#HealthInnovation
#ImmunoOncology
#Immunotherapy
#PrecisionMedicine
#SolidTumors

Contacts

contact@brenus-pharma.com

Social Media Profiles
Follow Brenus Pharma
More News From Brenus Pharma

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.

MADRID--(BUSINESS WIRE)--Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager,...

Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension

LYON, France--(BUSINESS WIRE)--Brenus Pharma today announced an €11 million ($12.6M) extension to its Series A round, bringing total capital raised since inception to €38 million ($43.5M). This funding reflects strong execution across clinical, regulatory, and business development milestones, de-risking STC-1010 (NCT06934538): lead clinical-stage in-vivo immunotherapy for MSS mCRC, while positioning the company’s proprietary platform for multi-asset expansion. The round was supported by strong...

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member

LYON, France--(BUSINESS WIRE)--Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE, who will remain an active board member. Eric brings extensive experience in healthcare innovation and value creation, having notably led BIOCORP through its development and acquisition by Novo Nordisk. Brenus also appoints Camilla SYLVEST, as a second independent director...
Back to Newsroom